Three years of funding, including tuition and stipend, is available to enroll in the PhD program INTERCEPT-MDS. The PhD student will be involved in a large, interdisciplinary project funded by the Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks under the European Commission Horizon 2020 program. If you are interested in joining the lab, please apply here.
Raphael Itzykson was promoted to Professor of Hematology at Assistance Publique Hôpitaux de Paris. Congrats!
Cancer cells know how to evolve and acquire resistance to conventional and targeted therapies. Lin et al. Nature Genetics have used chemogenomic screens to identify combination therapies that produce anticancer evolutionary traps, in which evading the first drug makes the cancer vulnerable to the second.
Our team is on the cover of The INSERM Gazette (In vivo n°5). to present the ATIP-Avenir program of CNRS/Inserm for which Alex Puissant was laureate in 2016. This program is based on stringent and strictly objective evaluations by external experts of the young scientists in France, and is now being followed by related research organizations in other EU countries.
Congratulations Alex for receiving the 24th Olga Sain Award from The Ligue Nationale Contre le Cancer for your very promising work on acute leukemia!
As a laureate of the Young Researchers Bettencourt Prize in 2011, Alex Puissant has been invited along with Xavier Jeunemaître (laureate in 1990), Béchir Jarraya (laureate in 2006) and Marina Kvaskoff (laureate in 2010), to share his story and explain how this prize can give momentum to a career and encourage to keep innovating in Sciences.
A new permanent research scientist, Dr Nina Fenouille, is now joining the Puissant lab to investigate mechanisms of chemoresistance in AML using innovative screening technologies.
Raphael Itzykson has recently discovered that the presence of multiple clones harboring muta-tions in the RTK/RAS pathway imparts an adverse prognosis in Core Binding Factor AML, while the presence of a single RTK/RAS clone has no impact on prognosis.
These findings have been published in The Blood Journal. Thanks to the support of The Fondation ARC, further work is ongoing to elucidate the role of the clonal interference of RTK/RAS pathway signaling in AML.
Among the best young researchers in life sciences, Alex Puissant has been selected by The Schlumberger Foundation for Education and Research (FSER) to support the creation of our lab, giving us the best chance to develop our work.
Alex Puissant is laureate of the 2017 ERC Starting Grants that fund the top talented young researchers across Europe. This funding will enable us to set up our lab and pursue ground-breaking ideas from basic science to leukemia treatment.